Skip to main content

Recalls — classification & coordination

note

Regulatory basis - MDR Art. 89 and Art. 95 / IVDR Art. 84 and Art. 90. EU medical device recalls are a subset of FSCAs. Unlike some other regulatory systems, the EU does not have a single standardised recall classification system — instead, the risk assessment under ISO 14971 and NCA discretion determine the urgency and scope.

warning

Disclaimer - This site provides general information only and does not constitute legal or regulatory advice. Always consult the official regulation text and a qualified regulatory professional.

What is a recall?​

In the EU context, a recall is a specific type of FSCA in which the manufacturer requires the return or removal from service of devices already distributed to customers or implanted in patients. Recalls are distinguished from other FSCAs (such as labelling updates or field modifications) by the requirement to physically retrieve or withdraw the device.

EU recall classification — no single EU-mandated system​

Unlike the US FDA, which has a formal three-tier recall classification (Class I / II / III), the EU does not mandate a single classification system for device recalls. Instead:

  • The urgency and depth of the recall is determined by the manufacturer's risk assessment under ISO 14971
  • NCAs may impose their own classification language or urgency requirements
  • The FSCA notification to NCAs communicates urgency and scope; NCAs assess whether the manufacturer's response is proportionate

In practice, many EU manufacturers use a risk-tiered system analogous to the FDA's in their internal procedures:

Internal tierCriteriaTypical response
High urgency (Class I equivalent)Reasonable probability of serious adverse health consequences or deathImmediate FSN; urgent NCA notification; 24–72 hour field response
Medium urgency (Class II equivalent)Remote probability of adverse health consequences, or consequences are temporary/reversibleFSN within days; NCA notification; 10–30 day field response
Low urgency (Class III equivalent)Unlikely to cause adverse health consequencesFSN within weeks; NCA notification; 30–60 day field response

Voluntary vs. mandatory recalls​

Voluntary recall (manufacturer-initiated FSCA)​

The vast majority of EU device recalls are voluntary — initiated by the manufacturer following their own risk assessment and regulatory reporting obligations under MDR Art. 89. The manufacturer:

  • Decides that an FSCA is necessary
  • Notifies NCAs
  • Issues an FSN
  • Implements the recall

Mandatory recall (NCA-ordered)​

Under MDR Art. 95, a national competent authority can order a manufacturer to take corrective action — including a recall — where it has determined that a device presents an unacceptable risk and the manufacturer has not taken adequate voluntary action.

NCA-initiated recalls are relatively rare in practice. NCAs typically engage with manufacturers first and give them the opportunity to act voluntarily before imposing mandatory action.

Commission safeguard (Art. 97)​

Where national measures are insufficient or inconsistent across member states, the European Commission may intervene under Art. 97 to impose EU-wide measures. This is a last resort used in exceptional circumstances.

Coordinating cross-border recalls​

For recalls affecting multiple EU member states, coordination is needed:

  1. NCA notification: the manufacturer notifies each NCA in the affected member states simultaneously via EUDAMED
  2. FSN translation: FSNs must be translated into the official language(s) of each affected member state
  3. Distributor chain notification: distributors and importers in each country must be notified and required to pass the FSN to their customers
  4. Cross-NCA coordination: NCAs may communicate through EUDAMED or directly to coordinate their oversight of the FSCA

The MDCG may be involved where a cross-border recall raises systemic regulatory questions.

Implanted devices — the most complex recalls​

Recalls of implanted devices (pacemakers, hip joints, stents) are the most operationally complex because:

  • Devices are inside patients — removal involves surgical risk that may exceed the risk of the device defect
  • Patient identification requires access to implant records and registries
  • A benefit-risk decision must be made for each patient: does the risk of explantation outweigh the risk of leaving the defective device in place?
  • Healthcare institutions must be alerted so they can identify affected patients

For implant recalls, the FSN typically includes:

  • Specific guidance on whether patients should be actively explanted or monitored
  • Enhanced follow-up protocols for patients with the affected device
  • Patient notification letter templates

Recall effectiveness monitoring​

After initiating a recall, the manufacturer must monitor and report on its effectiveness:

  • Track the return rate of recalled devices (number returned vs. number distributed)
  • Identify non-responsive customers and follow up
  • Document the disposition of returned devices (destroyed, analysed, refurbished)
  • Update NCAs on progress through EUDAMED
  • Close the recall with a final report once all affected devices are accounted for

NCAs may request progress updates and can escalate oversight if recall effectiveness is poor.

Official references​

ReferenceDescription
MDR Art. 89FSCA and recall reporting
MDR Art. 95NCA power to require corrective action
MDR Art. 97Commission safeguard procedure
IVDR Art. 84IVDR FSCA
IVDR Art. 90IVDR NCA corrective action powers
MDCG 2022-14FSCA and recall guidance
EN ISO 14971:2019Risk assessment for recall decisions